



Annual General Meeting – Chair Address

MELBOURNE Australia, 12 November 2021

Dear Shareholders,

A year ago none of us could have anticipated the astonishing extent to which the world would continue to change. Despite challenging conditions, it has been a year of outstanding achievement for Prescient team which has laid the foundations for significant future growth. We see these as just the beginning as our pipeline of innovative cancer therapies progress through their development.

Fortunately, the biotech community remains healthy if not robust, including big biotechs, many of which are new, big pharmas, and the biotech stock markets in general. IPOs and secondaries are continuing through one of the longest periods in the history of biotech. We believe this reflects the abundance of scientific and medical breakthroughs. In addition, the industry has played an incredible and significant role in the world during the pandemic.

As oncology disease continues to grow, especially with seemingly unstoppable obesity epidemic, the need for better solutions grows with it. Reflecting this need, more corporate partnership deals are being completed in oncology than any other modality between Big Pharma and biotech companies.

Existing cell therapy technology for cancer treatment has stepped onto the world stage and provided an amazing clinical benefit to suffering patients in its initial application. It has been a dazzling launch of a new approach.

In many ways, cell therapies, such as CAR-T, are the ultimate personalised medicine, as it seeks to harness a patient's own immune system to fight cancer. Something long promised by scientists.

This initial clinical success is leading to a higher demand for innovation in cell therapy technology. This is why the management and board chose this time to target cell therapies. We plan to take personalised medicine to the next level with next generation cell therapy technologies. We believe this is a key platform that can create controllable, flexible CAR-T products that can be directed against a variety of different cancer diseases.

We also believe that the industry and investment community is only beginning to appreciate the capabilities of OmniCAR.

The development of Prescient's other targeted therapies, PTX-100 and PTX-200 continue to progress through the clinic and we look to build on the encouraging results observed so far. This was demonstrated after the reporting period with the promising results from the PTX-100 Phase 1b study, which exhibited a strong safety profile, together with an encouraging efficacy signal in two patients with aggressive T cell lymphomas. This will now be pursued in an expansion cohort in this disease under the enthusiastic leadership of Professor H. Miles Prince, AM.



Additionally, Prescient has been carrying out a number of projects that are currently in stealth mode but have the potential to add significant value for the Company.

Taken collectively, one can see that this is a very busy and exciting period for Prescient, and one that has the potential to create significant value for shareholders and deliver promising therapies for cancer patients.

The Company continues to progress development whilst managing finances responsibly. Operating cash outflows for the year were \$3.97 million, as compared with \$2.31 million in 2020, and the consolidated entity ended the year with \$16.09 million in cash (2020: \$7.35 million). Details of our financial performance is found in the Financial Review on page 7 of this report.

We would like to acknowledge the insights and commitment of the Board over the past year. We also wish to acknowledge the work of our executive team for their resilience and their commitment to Prescient in the face of significant challenges and disruption.

Prescient continues to work with the best collaborators and takes a global view in doing so. Our licensing partnerships with some of the world's leading institutes at Yale University; University of Oxford and Pennsylvania University, our clinical work with world renowned oncologists such as Professor Prince, our research partnership with the world-leading Peter MacCallum Cancer Centre are examples of this.

The Board and Management thank our growing number of shareholders for their support over the year. We look forward to the coming year with great optimism and excitement. All of us are focused and driven to succeed in our mission to improve cancer treatment by giving doctors the tools they need to help patients with cancer live longer, better quality lives.

Thank you for your support and investment in Prescient Therapeutics.

- Ends -

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter [@PTX_AUS](#) and [LinkedIn](#).

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries:
Sophie Bradley – Reach Markets
+61 450 423 331
ir@reachmarkets.com.au

Media enquiries:
Andrew Geddes – CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au



About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

Cell Therapy Enhancements: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound has previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer, with a Phase 1b/2 trial currently underway in relapsed and refractory AML.

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking



statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward- looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward- looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward- looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website : [Supplemental COVID-19 Risk Factors](#)